Filing Details
- Accession Number:
- 0000947871-17-000078
- Form Type:
- 13G Filing
- Publication Date:
- 2017-02-01 17:03:42
- Filed By:
- Merlin Biomed Private Equity Advisors, L.l.c.
- Company:
- Trillium Therapeutics Inc. (NASDAQ:TRIL)
- Filing Date:
- 2017-02-01
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Merlin Biomed Private Equity Advisors | 443,631 | 443,631 | 443,631 | 5.46% | ||
| Merlin Nexus IV | 443,631 | 443,631 | 443,631 | 5.46% | ||
| Dominique S mon | 443,631 | 443,631 | 443,631 | 5.46% |
Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No 4)*
Trillium Therapeutics Inc.
(Name of Issuer)
Common Stock, No Par Value
(Title of Class of Securities)
89620X506
(CUSIP Number)
December 31, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed.
o Rule 13d-1(b)
þ Rule 13d-1(c)
o Rule 13d-1(d)
| * | The foregoing percentage is based upon 7,817,883 shares outstanding as of September 30, 2016, as set forth in the Interim Condensed Consolidated Financial Statements included in Exhibit 99.1 to the Issuer’s report on Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2016 and takes account of 303,631 shares subject to warrants held by the Reporting Persons. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 89620X506 | SCHEDULE 13G | |
| 1 | NAME OF REPORTING PERSONS Merlin Biomed Private Equity Advisors, LLC (IRS No. 13-4178606) | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER - 0 - | ||
| 6 | SHARED VOTING POWER 443,631 | |||
| 7 | SOLE DISPOSITIVE POWER - 0 - | |||
| 8 | SHARED DISPOSITIVE POWER 443,631 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 443,631 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | o | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.46%(1) | |||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA | |||
(1) The foregoing percentage is based upon 7,817,883 shares outstanding as of September 30, 2016, as set forth in the Interim Condensed Consolidated Financial Statements included in Exhibit 99.1 to the Issuer’s report on Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2016 and takes account of 303,631 shares subject to warrants held by the Reporting Persons.
| CUSIP No. 89620X506 | SCHEDULE 13G | |
| 1 | NAME OF REPORTING PERSONS Merlin Nexus IV, L.P. | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER - 0 - | ||
| 6 | SHARED VOTING POWER 443,631 | |||
| 7 | SOLE DISPOSITIVE POWER - 0 - | |||
| 8 | SHARED DISPOSITIVE POWER 443,631 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 443,631 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | o | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.46%(1) | |||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO | |||
(1) The foregoing percentage is based upon 7,817,883 shares outstanding as of September 30, 2016, as set forth in the Interim Condensed Consolidated Financial Statements included in Exhibit 99.1 to the Issuer’s report on Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2016 and takes account of 303,631 shares subject to warrants held by the Reporting Persons.
| CUSIP No. 89620X506 | SCHEDULE 13G |
| 1 | NAME OF REPORTING PERSONS Dominique Sémon | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o | | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER - 0 - | ||
| 6 | SHARED VOTING POWER 443,631 | |||
| 7 | SOLE DISPOSITIVE POWER - 0 - | |||
| 8 | SHARED DISPOSITIVE POWER 443,631 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 443,631 | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | o | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.46%(1) | |||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN | |||
(1) The foregoing percentage is based upon 7,817,883 shares outstanding as of September 30, 2016, as set forth in the Interim Condensed Consolidated Financial Statements included in Exhibit 99.1 to the Issuer’s report on Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2016 and takes account of 303,631 shares subject to warrants held by the Reporting Persons.
| CUSIP No. 89620X506 | SCHEDULE 13G |
| Item 1 | (a). | Name of Issuer: |
Trillium Therapeutics Inc.
| Item 1 | (b). | Address of Issuer’s Principal Executive Offices: |
96 Skyway Avenue,
Toronto, Ontario M9W 4Y9
Canada
| Item 2 | (a). | Name of Person Filing: |
This Schedule 13G is being filed by each of the following persons (each, a “Reporting Person” and together, the “Reporting Persons”):
| (i) | Merlin BioMed Private Equity Advisors, LLC |
| (ii) | Merlin Nexus IV, L.P. |
| (iii) | Dominique Sémon |
See Exhibit B for the Reporting Persons’ agreement for a joint filing of a single statement on their behalf.
| Item 2 | (b). | Address of Principal Business Office: |
424 West 33rd Street, Suite 520
New York, NY 10001
| Item 2 | (c). | Citizenship: |
Merlin BioMed Private Equity Advisors, LLC is a Delaware Limited Liability Company. Merlin Nexus IV, L.P. is a Delaware Limited Partnership. Dominique Sémon is a citizen of Switzerland.
| Item 2 | (d). | Title of Class of Securities: |
Common Stock, No Par Value (the “Common Stock”).
| Item 2 | (e). | CUSIP Number: |
89620X506
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
| CUSIP No. 89620X506 | SCHEDULE 13G |
| Item 4. | Ownership: |
* See Attachment A.
| (a) | Amount beneficially owned: 443,631 |
| (b) | Percent of class: 5.46% |
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or to direct the vote: -0- |
| (ii) | Shared power to vote or to direct the vote: 443,631 |
| (iii) | Sole power to dispose or to direct the disposition of: -0- |
| (iv) | Shared power to dispose or to direct the disposition of: 443,631 |
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this Statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. o
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Various other persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from sale of, the securities whose ownership is reported on this Schedule 13G. No other person’s interest in such securities relates to more than five percent of the class.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
| Item 9. | Notice of Dissolution of Group. |
Not applicable.
| Item 10. | Certifications. |
By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
| CUSIP No. 89620X506 | SCHEDULE 13G |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
January 31, 2017
| Merlin Biomed Private Equity Advisors, LLC | ||||
| By: | /s/ Dominique Sémon | |||
| Name: | Dominique Sémon | |||
| Title: | Managing Member | |||
| Merlin Nexus IV, L.P. | ||||
| By: | Merlin Nexus IV, LLC, General Partner | |||
| By: | /s/ Dominique Sémon | |||
| Name: | Dominique Sémon | |||
| Title: | Managing Member | |||
| Dominique Sémon | ||||
| By: | /s/ Dominique Sémon | |||
| Name: | Dominique Sémon | |||
ATTACHMENT A
As of December 31, 2016 Merlin Nexus IV, L.P. (“Merlin IV”) was the holder of 443,631 shares of Common Stock, no par value, of Trillium Therapeutics Inc. (“Common Stock”). Merlin BioMed Private Equity Advisors, LLC, a Delaware limited liability company (“Merlin”) is the investment adviser to Merlin IV. Dominique Sémon is the Managing Member of Merlin. As of December 31, 2016, Merlin IV, Merlin and Dominique Sémon may be deemed, including by virtue of their mutual affiliation, as sharing voting power and dispositive power, and consequently to be beneficial owners, of the 443,631 shares of Common Stock held by Merlin IV, constituting 5.46% of the outstanding shares of Common Stock. The foregoing percentage is based upon 7,817,883 shares outstanding as of September 30, 2016, as set forth in the Interim Condensed Consolidated Financial Statements included in Exhibit 99.1 to the Issuer’s report on Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2016 and takes account of 303,631 shares subject to warrants held by the Reporting Persons.